Kevin W. Chamberlin, PharmD, FASCP

Study results show improvement in progression-free survival at 22 months.

On June 26, 2024, the FDA approved ensifentrine (Ohtuvayre) for the treatment of COPD.

The FDA approved ceftobiprole medocaril sodium for injection (Zevtera) in April 2024.

The novel drug elranatamab-bcmm (Elrexfio) received accelerated FDA approval on August 14, 2023, for treating adults with relapsed or refractory multiple myeloma.

Relyvrio is intended to slow the disease progression of amyotrophic lateral sclerosis.

Acid sphingomyelinase deficiency is a rare, progressive genetic disease associated with significant morbidity and mortality.